+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure



Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure



Journal of Infectious Diseases 184(12): 1608-1612



In a nonrandomized study of nonoccupational postexposure prophylaxis (PEP), a cross-sectional evaluation of subjects who were the source of human immunodeficiency (HIV) exposure was performed to characterize partners of index subjects seeking nonoccupational PEP against HIV. Among 401 index subjects, 64 (16%) recruited a source subject. Those in a steady relationship and those who knew that the source subject was HIV antibody positive were more likely to recruit their source subject. Source subjects reported high rates of past (78%) and current (69%) antiretroviral use; 46% of those using antiretroviral drugs had detectable plasma HIV-1 RNA levels. Antiretroviral resistance was detected in many source subjects who reported any use of antiretrovirals and was rare among source subjects who reported no history of antiretroviral use. Clinicians often make treatment decisions on the basis of incomplete knowledge of the source subject's HIV status or antiretroviral treatment history. The treatment history, particularly nonuse of a class of antiretroviral drugs, can be used to predict drug resistance.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011173790

Download citation: RISBibTeXText

PMID: 11740738

DOI: 10.1086/324580


Related references

Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. Journal of Infectious Diseases 183(5): 707-714, 2001

Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Archives of Internal Medicine 164(1): 46-54, 2004

Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. Mmwr. Recommendations and Reports 54(Rr-2): 1-20, 2005

Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. Aids 18(15): 2065-2073, 2004

Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault. American Journal of Medicine 106(3): 323-326, 1999

Postexposure prophylaxis against human immunodeficiency virus infection after sexual assault. Pediatric Infectious Disease Journal 21(10): 959-960, 2002

Announcement: Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016. Mmwr. Morbidity and Mortality Weekly Report 65(17): 458-458, 2016

Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus. Pediatrics 111(6 Pt 1): 1475-1489, 2003

Human immunodeficiency virus postexposure prophylaxis following occupational HIV exposure Findings from the HIV PEP Registry. Clinical Infectious Diseases 25(2): 444, 1997

Postexposure prevention of HIV following sexual or drug use exposure The role of source partner information in determining true HIV exposure. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 415, 1998

Human immunodeficiency virus postexposure prophylaxis for occupational exposure in a medical school hospital in Thailand. Journal of Hospital Infection 67(4): 344-349, 2007

Factors influencing human immunodeficiency virus postexposure prophylaxis requests after low-risk occupational exposure. Military Medicine 167(6): 506-509, 2002

Frequency of percutaneous injuries requiring postexposure prophylaxis for occupational exposure to human immunodeficiency virus. Infection Control and Hospital Epidemiology 19(7): 504-506, 1998

Update on emerging infections: news from the Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. Annals of Emergency Medicine 46(1): 82-86, 2005

Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). Journal of Virology 74(20): 9771-9775, 2000